F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs

Health
By Rebecca Robbins from NYT Health https://ift.tt/VBFW9eC
via IFTTT Regulation and Deregulation of Industry, Prices (Fares, Fees and Rates), Biotechnology and Bioengineering, Drugs (Pharmaceuticals), Generic Brands and Products, Clinical Trials, Inventions and Patents The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.

Comments

Popular posts from this blog

Should the Autism Spectrum Be Split Apart?

The Jarring Contradiction at the Heart of Kennedy’s Agenda